Archives

  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Adefovir dipivoxil sensitizes vemurafenib resistant

    2022-05-09


    3.6. Adefovir dipivoxil sensitizes vemurafenib-resistant colon cancer Hydrocortisone to vemurafenib
    Given that CDK1 activation leads to vemurafenib resistance in colon cancer cells and AD inactivates CDK1 though disrupting the KCTD12-CDK1 interaction, we next investigated whether AD treatment enhances the sensitivity of VR colon cancer cells to vemurafenib. Using WST-1 
    and colony formation assays, we found that combined use of AD and vemurafenib exerted a more potent effect on suppression of cancer cell proliferation compared to either vemurafenib or AD treatment alone in CDK1-expressing colon cancer cells (Fig. 6A and B). To examine whe-ther AD reverses the resistance of CDK1-overexpressing colon cancer cells to vemurafenib in vivo, HT29 cells with ectopic expression of CDK1 were subcutaneously injected into nude mice, and tumor-bearing mice were treated with vemurafenib, AD alone or a combination. Although vemurafenib or AD had no effect or only a modest anti-proliferative effect on tumors, combined vemurafenib and AD exerted a significantly synergistic effect on suppressing the growth of tumor xenografts (Fig. 6C). Moreover, immunohistochemical analysis of Ki-67 prolifera-tion index also provided evidence that tumor cell proliferation was significantly inhibited by combined use of vemurafenib and AD (mean index decreased from 51.7% in the vehicle-treated group to 47.0% in the vemurafenib-treated group and 22.0% in the AD/Vemurafenib combination-treated group) (Fig. 6D). Western blot analysis of tumor xenografts showed that CDK1 activation in VR tumors was significantly inhibited by combined use of vemurafenib and AD (Fig. 6E). Con-sidering the lack of significant changes in body weight (Fig. 6F), our results demonstrate treatment efficacy and safety of AD as a vemur-afenib sensitizer in colon cancer cells. r> 4. Discussion
    B-Raf is frequently overexpressed in different cancers and plays an important role in tumorigenesis [7,8]. Previous studies have demon-strated that vemurafenib exhibits significant effects on suppressing melanoma cell proliferation by targeting B-Raf/B-Raf V600E. However, the mechanism by which vemurafenib suppresses cancer cell pro-liferation remains unclear, and the therapeutic efficacy of vemurafenib on colon cancer is reduced compared to melanoma [13]. Understanding the molecular mechanisms underlying drug resistance can provide clues to identify potential targets for development of anticancer drugs. A recent study demonstrated that colon cancer is unresponsive to ve-murafenib treatment due to feedback activation of EGFR [13]. More-over, cancer cells will also be unresponsive to targeted drugs if certain “front-line proteins”, including direct performers, such as cyclins and epithelial-mesenchymal transition (EMT) factors that receive signals from upstream factors and lead to tumorigenesis and cancer develop-ment, are activated [45]. This finding suggests that targeting “front-line proteins” may be a better strategy for overcoming tumor resistance to chemotherapeutic drugs. In this study, we uncovered the mechanism for chemoresistance of colon cancer cells to vemurafenib and aimed to resolve this problem by focusing on “front-line proteins”. Using IPA analysis, we found that cell cycle checkpoint signaling is one of the biological processes affected by vemurafenib, and expression of CDK1, one of the “front-line proteins”, was significantly decreased. Further-more, CDK1 overexpression significantly increased colon cancer cell resistance to vemurafenib, indicating that CDK1 is an effector of ve-murafenib and plays an important role in vemurafenib resistance in colon cancer (Figs. 1–2, Supplementary Fig. S1).